Altimmune Announces Data Presentation on ALT-801, its Balanced and Long-Acting GLP-1/Glucagon Receptor Dual Agonist for NASH, at the Digital International Liver Congress™ 2020
“We are excited to share the compelling preclinical body of work on the weight loss, NASH improvement and gene regulatory signatures induced by ALT-801 at EASL as we prepare to commence our first in human Phase 1 trial next quarter,” said
Employing the well-established Gubra mouse model, animals with biopsy-confirmed NASH received ALT-801 (5 or 10 nmol/kg), semaglutide (10 nmol/kg), a GLP-1 receptor agonist or vehicle subcutaneously for 12 weeks. ALT-801 demonstrated statistically superior reductions (p ≤ 0.05) in body weight, liver weight, plasma ALT, liver triglycerides and cholesterol, plasma cholesterol, NAFLD activity scores, and fibrosis markers compared to semaglutide. Principal component analysis differentially clustered genes regulated by ALT-801 from those regulated by semaglutide, consistent with a unique gene regulatory signature associated with glucagon receptor activation. ALT-801 also resulted in greater suppression of archetypal genes involved in de novo lipogenesis and fatty acid uptake, inflammation, hepatocellular death, fibrosis and stellate cell activation than semaglutide.
The Phase 1 trial will be conducted in
Details for the poster presentation are as follows:
Title: | GLP-1/Glucagon Dual Receptor Agonist ALT-801 is Superior to Semaglutide in Improving NASH Endpoints in a Biopsy-Confirmed DIO Mouse Model (FRI-117) |
Presenter: | |
Date/Time: | August 28, 2020 at 8:30 to 18:30 GMT |
A copy of the poster will be accessible on the Events section of the Altimmune website.
About ALT-801
ALT-801 is a novel peptide-based dual GLP-1/glucagon receptor agonist that is designed to treat the obesity and metabolic dysfunction that causes non-alcoholic steatohepatitis, or NASH. NASH, the most severe form of non-alcoholic fatty liver disease, or NAFLD, involves multiple metabolic pathways leading to the abnormal accumulation of liver fat, toxic lipid metabolites, and inflammation, leading to fibrosis or eventually liver cancer. We believe the treatment of obesity is the cornerstone of treating NASH and the principal morbidities of NASH. As observed in a well-established preclinical model of the disease, ALT-801 was capable of inducing significant weight loss with concomitant decreases in liver fat, inflammation and fibrosis.
About Altimmune
Altimmune is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease. Our diverse pipeline includes proprietary intranasal vaccines for COVID-19 (AdCOVID™), anthrax (NasoShield™) and influenza (NasoVAX™); an intranasal immune modulating therapeutic for COVID-19 (T-COVID™); and next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell™). For more information on Altimmune, please visit www.altimmune.com.
Forward-Looking Statement
Any statements made in this press release relating to future financial or business performance, conditions, plans, prospects, trends, or strategies and other financial and business matters, including without limitation, the timing of key milestones for our clinical assets, the initiation and timing of the ALT-801 Phase 1 clinical trial in Q4 2020, the timing of the date readout expected in the spring of 2021, our ability to manufacture ALT-801, and the prospects for regulatory approval, commercializing or selling any product or drug candidates, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In addition, when or if used in this press release, the words “may,” “could,” “should,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “predict” and similar expressions and their variants, as they relate to
Investor Contacts: | |
Chief Financial Officer | |
Phone: 240-654-1450 | 617-430-7577 |
wbrown@altimmune.com | arr@lifesciadvisors.com |
Media Contact: | |
Phone: 212-687-8080 | |
altimmune-svc@sardverb.com |
Source: Altimmune, Inc.